Evolution of ceftazidime–avibactam resistance driven by mutations in double-copy blaKPC-2 to blaKPC-189 during treatment of ST11 carbapenem-resistant Klebsiella pneumoniae

IF 5 2区生物学 Q1 MICROBIOLOGY

mSystems Pub Date : 2024-09-17 DOI:10.1128/msystems.00722-24

Xiaofan ZhangYinrong XieYing ZhangTailong LeiLongjie ZhouJiayao YaoLin LiuHaiyang LiuJintao HeYunsong YuYuexing TuXi Li1Centre of Laboratory Medicine, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China2Department of Clinical Laboratory, Feicheng Hospital of Traditional Chinese Medicine, Feicheng, Shandong, China3Department of Clinical Laboratory, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, Fujian, China4Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China5Center for General Practice Medicine, Department of Infectious Diseases, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China6Department of Critical Care Medicine, Tongde Hospital of Zhejiang Province, 234 Gucui Road, Hangzhou, Zhejiang, ChinaXiyang Dong

引用次数: 0

Abstract

mSystems, Ahead of Print.

查看原文本刊更多论文

在治疗 ST11 耐碳青霉烯类肺炎克雷伯菌过程中，双拷贝 blaKPC-2 基因突变导致头孢他啶-阿维菌素耐药性的演变

mSystems, Ahead of Print.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

mSystems Biochemistry, Genetics and Molecular Biology-Biochemistry

CiteScore

10.50

自引率

3.10%

发文量

308

审稿时长

13 weeks

期刊介绍： mSystems™ will publish preeminent work that stems from applying technologies for high-throughput analyses to achieve insights into the metabolic and regulatory systems at the scale of both the single cell and microbial communities. The scope of mSystems™ encompasses all important biological and biochemical findings drawn from analyses of large data sets, as well as new computational approaches for deriving these insights. mSystems™ will welcome submissions from researchers who focus on the microbiome, genomics, metagenomics, transcriptomics, metabolomics, proteomics, glycomics, bioinformatics, and computational microbiology. mSystems™ will provide streamlined decisions, while carrying on ASM''s tradition of rigorous peer review.